Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer Biomet’s Dental And Spine Spin-Off Will Be Called ZimVie

Executive Summary

The company also named ZimVie’s management team, led by CEO Vafa Jamali.

You may also be interested in...



ZimVie Wins Investigational Device Exemption For Disc Replacement Device, Plans To Begin Study

The US FDA has granted Investigational Device Exemption to Colorado life sciences company ZimVie for its cervical disc implant. The approval means the company can begin enrolling patients in a study to further evaluate the device.

Analysts Applaud Zimmer Biomet’s Dental And Spine Spin-Off, Focus On Orthopedics

Zimmer Biomet’s CEO Bryan Hanson expects the spin-off will help streamline the company and optimize resources for innovation.

News We're Watching: Tricuspid Procedure Boom, Boston Scientific Borrows $2Bn, And More

Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, GE Healthcare and Biofourmis announced a deal to collaborate on virtual care; Cleerly touts a new CPT code for its Ischemia cardiac diagnostic software; Boston Scientific announced how it plans to pay for Axonics; a Wells Fargo survey suggests the market for transcatheter tricuspid valve repair and replacement will grow faster than previously imagined; Virtual Incision earns FDA de novo authorization for its MIRA miniaturized surgical system for colectomy procedures; and MMI and Fabric announce major financing rounds.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel